Granules India gains on product in-licensing pact with US firm

The company's US arm has exclusive agreement with USpharma Windlas, LLC for product in-licensing

Shares of Granules India were up over 2% at Rs 143 on the Bombay Stock Exchange after the company's wholly-owned US subsidiary Granules Pharmaceuticals, Inc., entered into an exclusive agreement with USpharma Windlas, LLC for product in-licensing.

Following the agreement, Granules Pharmaceuticals, Inc., has acquired the exclusive rights from USpharma Windlas, LLC to market and distribute four products in the USA.

The stock opened at Rs 140 and touched a high of Rs 144. At 2pm, over 1.6 million shares were traded on both the stock exchanges.